CD274 and neoplasm: In line with these results, the association between the Bcl-2 inhibitor venetoclax, the next-generation anti-CD20 mAb obinutuzumab and the anti-PD-L1 mAb atezolizumab led to high rates of response in previously untreated RS patients (111, 112), demonstrating one more time how immunotherapeutic approaches aiming a different targets can exploit a synergistic action against tumor cells.